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SPECT allows registration of regional cerebral blood ﬂow (rCBF) which is altered in a characteristic temporoparietal pattern in
Alzheimer’s Dementia. Numerous studies have shown the diagnostic value of reduced cerebral blood ﬂow and metabolic changes
using perfusion SPECT and FDG-PEPT in AD diagnosis as well as in diﬀerential diagnosis against frontotemporal dementia,
dementia with Lewy bodies and vascular disease. Recently more pathophysiology-based biomarkers in CSF and Amyloid-PET
tracershavebeen developed thatprobablyhaveahigherdiagnosticaccuracy thanthe moreindirect rCBFchangesseen inperfusion
SPECT. In the paper review, we describe recent advances in AD biomarkers as well as improvements in the SPECT technique.
1.Introduction
Memory problems in elderly patients are common and can
be due to a wide range of conditions. Alzheimer’s Disease
(AD) accounts for a large amount of cases, especially when
gradual onset and further cognitive problems like aphasia,
apraxia, or reduced activities of daily life are present. AD
originally has been a pathologic diagnosis. The “golden
standard” of AD are comprehensive clinical criteria (like
NINCDS-ADRDA,DSM-IV, or ICD-10). These criteria have
been validated against pathology with a wide range of
sensitivity (65%–100%) and speciﬁcity (65%–90%) [1].
Thus, during the last decades, imaging and cerebrospinal
ﬂuid (CSF) taps were then performed to rule out secondary
memory disorders, for example, due to intracranial mass
or infection (like syphilis). As a ﬁrst approach to in vivo
AD imaging, single proton emission computed tomography
(SPECT) with perfusion tracers was developed and validated
approximately 25 years ago. Perfusion SPECT shows a
characteristic (nonvascular) pattern in parietal-temporal
cortical areas that indirectly reﬂect the underlying spatial
distribution of neuroﬁbrillary and amyloid pathology. The
coupling of fading neural activity and glucose metabolism
to reduced regional cerebral blood ﬂow (rCBF) allowed
for the ﬁrst time real albeit indirect “functional imag-
ing” in neurodegenerative diseases using SPECT and later
FDG-PET. More recently, advances in CSF protein assays
and the development of speciﬁc amyloid-binding Positron
Emission Tomography (PET) tracers allowed direct and
pathophysiology-based tests and imaging. Here we would
like to review the diagnostic value, accuracy, advantages, and
disadvantages of perfusion SPECT in comparison to these
more advanced CSF and PET biomarkers.
2.Diagnostic ValueofPerfusionSPECT
Since 1991 more than 50 studies have been performed to
compare the diagnostic value of SPECT (mostly 99mTc-
HMPAO) in AD versus normal volunteers, patients without
neurodegenerativedementia(likedepression)orotherforms
of dementia like frontotemporal dementia (FTD), dementia
with Lewy bodies (DLB), or vascular dementia [2]. Taken
together these studies clearly showed added value of SPECT
for or against a clinical diagnosis of AD. A comprehensive
review of Dougall et al. [3] identiﬁed 389 publications on2 International Journal of Alzheimer’s Disease
this issue. After exclusion of nonrelevant studies using a
methodology checklist the authors found 37 studies of clin-
ical AD versus normal controls (comprising 1559 subjects)
and 13 studies of AD versus nondemented control patients
(1082 patients). The case-control studies with AD patients
versus normal subjects were too heterogeneous to compare.
The studies of clinical AD versus nondemented patients
showed pooled sensitivities/speciﬁcities of 66% and 79%,
respectively,yielding a diagnosticoddsratio of8.2[3].Inour
own data base, we found sensitivities of 48%–60% [4]a n da
speciﬁcity of 90% [5]. Comparison of blinded SPECT versus
a pathological conﬁrmed diagnosis of dementia yielded
SPECT sensitivity/speciﬁcity of 63%–86% and 73%–93%
[6, 7]. Another important clinical question is the value of
perfusion SPECT to predict progression from mild cognitive
impairment (MCI) to AD. Devanand et al. [8]f o u n da
sensitivity of only 42% but a speciﬁcity of 82% for perfusion
SPECT. Taken together these results suggest that SPECT has
a sensitivity for AD that is most likely below the desired
threshold of a valid biomarker, but a high speciﬁcity, making
SPECT at least a useful diagnostic tool to rule out AD. In
Table 1 the individual components of perfusion SPECT are
displayed against other techniques.
3.ComparisonofPerfusionSPECTand
FDG-PET
ThestandardradionuclideinclinicalPETcentersisFDG(18F
tagged to Deoxyglucose). FDG has long been the traditional
method to measure secondary glucose metabolism changes
downstream the neurodegenerative process in AD. Since
cerebral metabolism and blood ﬂow are coupled, there is
a similar pattern of regional disturbed glucose metabolic
rates (rCMRGlu) in the temporal-parietal cortex, less in the
prefrontal area as mentioned before. The ﬁrst description
appeared in 1982 by Farkas et al. [9]. Since then, many other
groups conﬁrmed the diagnostic value of FGG-PET in AD.
In a meta-analysis of 15 articles, Patwardhan et al. found a
pooledsensitivity of86%andaspeciﬁcityof86%[10].FDG-
PET and perfusion SPECT are the two most prominently
available functional imaging methods available to clinicians
worldwide.
Direct comparison of both techniques in the same pop-
ulation has not been performed to our knowledge. When
comparing the diagnostic accuracy based on meta-analytic
data, there is some evidence for a higher sensitivity and
speciﬁcity ofFDG-PET when compared to perfusion SPECT.
4.Diagnostic Valueof CSF-BasedBiomarkers
Since the identiﬁcation of Amyloid Precursor Protein (APP)
inADpathophysiology,therehavebeeneﬀortstoﬁndappro-
priate APP-based CSF tests. However, initial assays measured
all amyloid peptides and were not speciﬁc enough. After the
pioneering work of Motter et al. in 1995 [11]w h of o u n da
speciﬁc reduction of beta-amyloid peptide-42 in CSF, these
results were then conﬁrmed by many other groups. On
average there is a reduction of beta-amyloid peptide-42 of
approximately 40%–50%, and the tests have a sensitivity
and speciﬁcity of approximately 85%. Other publications
evaluated whether tau-pathology is also reﬂected in CSF
changes.CSFlevelsofthemicrotubule-associatedtauprotein
aretypicallyincreased (onaverage2.5-fold)inADandreﬂect
neuronaldamage [12].Datafrommore than35single-center
studies comprising more than 2500 AD patients and 1400
controls, meta-analyses, and consensus papers [13]a r en o w
available. When the speciﬁcity is set to 90% (which is a
desirable value for biomarkers) total-tau has a sensitivity of
app. 80% [14].
Hyperphosphorylation of tau (at position Threonine 181,
231 and Serine 199) occurs solely in AD and is therefore
theoretically a more speciﬁc biomarker. However, studies
showed large diﬀerences in sensitivity and speciﬁcity. A
meta-analysis of 51 single-center studies by Mitchell [15]
showed a pooled sensitivity of 78% and a speciﬁcity of
88% against patients without cognitive impairment. More
recently, the diﬀerent CSF markers have been combined [16]
and the interpretation algorithms have been reﬁned [17].
When evaluated in larger multicenter trials in patients with
MCI, AD and nondemented patients or healthy subjects,
the sensitivity of the combined CSF biomarkers (Amyloid
peptide-42- and tau markers) to detect AD in MCI patients
was then 85%–95% and the speciﬁcity 72%–83% [18, 19].
Other biomarkers like soluble APP are under investigation
[20] and need to be validated. As a disadvantage it turned
out in the CSF multicenter trials that there are larger than
expected interlaboratory discrepancies [21].
5.Amyloid-and Tau-PET
The Pittsburgh Compound-B (11C-PiB) was the ﬁrst of a
new family of PET tracers that have shown to be of high
diagnostic value in AD. Speciﬁc binding of PiB to brain
Amyloid has been extensively studied in case-control studies
and longitudinal observations since 2004 [22]. The area
under the curve (AUC) in receiver operator characteristics
(ROCs) for PiB is around 0.8-0.9 and can be improved to
0.94 when reserve variables like education, brain volume,
gender, physical health, and medications are taken into
account [23]. The main limitation for 11C-based PET tracers
is their short half-life (appr. 20 minutes) which restricts
their use to dedicated research sites with on-site cyclotrons
and radiochemistry labs. 18F-based tracers have a longer
half-life (appr. 110 minutes). The ﬁrst 18Ft r a c e rf o rA D
was FDDNP and developed to recognize both plaques and
tangles. This could overcomethe problemthat some patients
have extensive plaque formation but no dementia. The AUC
for global rating of the FDDNP-PET could be up to 1.0
for AD versus control, 0.95 for MCI versus control and
0.98 for AD versus MCI. These promising results suggest
that Amyloid-PETs or combined Amyloid-Tau-PETs may
have a diagnostic value superior to other imaging tools
like FDG-PET or volumetric MRI [24]i np r e v a l e n tA D .
Also, these tracers have been studies in MCI as a tool for
early diagnosis but the results need to be validated in
independent studies. Other studies with 18F-PET markersInternational Journal of Alzheimer’s Disease 3
Table 1: Perfusion SPECT versus biomarkers in AD.
Method FDG-PET Perfusion-SPECT CSF Amyloid-PET
First description Farkas et al., 1982 [9] Launes et al., 1991 [2] Motter et al., 1995
[32] Klunk et al., 2004 [22]
Diagnostic accuracy
Sensitivity
Speciﬁcity
Meta-analysis
[10]
86% (CI: 76%–93%)
86% (CI: 72%–93%)
Yes
[3]
66% (CI: 62%–69%)
79% (CI: 75%–83%)
Yes
[13, 15]
80%–85%
85%–90%
Yes
[23]
appr. 85%–100%%
appr. 85%–100%
No
Clinical availability Academic centers Greater hospitals Theoretically
everywhere Academic centers
Equipment Cycloton Gamma-camera ELISA reader Cycloton
Cost Estimation >1000 EUR <300 EUR <200 EUR >2000 EUR
Expertise for
resultinterpretation High High High High
Treatment options if test
positive
MCI: negative MCI: negative MCI: negative MCI: negative
AD: positive AD: positive AD: positive AD: positive
DLB: oﬀ-label
FTD: negative
CI: 95% conﬁdence interval. MCI: mild cognitive impairment.
like Flutemetamol (PiB with 18F) are in phase II clinical
studies [25]. Florbetapir (18F-AV-45) is the most widely
studied 18F Amyloid imaging agent [26] and could receive
FDA approval within next time. Other compounds like Flor-
betaben(ClinicalTrialNCT01020838)areinphaseIIIclinical
studies.
6.DifferentialDiagnosis: Vascularand
FrontotemporalDementia,Dementia with
Lewy-Bodies
Although AD is the most prevalent dementia, several other
neurodegenerative disorders have to be taken into account
by the clinician. Vascular dementia is usually characterized
by a past medical history with the presence of typical car-
diovascular risk factors, stepwise deterioration, and vascular
lesions on MRI or CT. Still, Perfusion SPECT has been used
to discriminate vascular from primary neurodegenerative
dementia. According to the meta-analysis of Dougall et al.,
the pooled weighted sensitivity and speciﬁcity against AD is
71%, respectively 76% [3].
Using clinical features alone, the diﬀerential diagnosis of
frontotemporal dementia (FTD) and Dementia with Lewy-
Bodies (DLB) is sometimes diﬃcult. FTD is a heterogeneous
disease and in contrast to AD no established speciﬁc and
validated biomarkers are available. In the above-mentioned
review of Dougall et al. 2004 [3], the authors found a pooled
sensitivity and speciﬁcity of SPECT for discriminating AD
from FTD of72% and 78%, respectively The diagnostic odds
ratio was 8.4 and is in the same range as that for AD versus
control. In pathologically conﬁrmed FTD cases, McNeill et
al. found a sensitivity of bilateral frontal lobe CBF reduction
of 80% and a speciﬁcity of 81% versus AD [27]. In a larger
sample of FTD patients, Mendez et al. found a sensitiv-
ity/speciﬁcity of 91% and 75% and a negative predictive
valueof90% [28].These resultssuggestthatSPECTprovides
useful additional information in discriminating AD from
FTD. Some patients with Dementia with Lewy bodies (DLB)
have prominent cognitive deﬁcits but MRI usually does not
show the characteristic global atrophy as seen in AD. Here
several nuclear medicine techniques may be of advantage
like assessment of occipital hypoperfusion alone [29]o ri n
combination with MRI [30]. If symptoms of Parkinson’s
disease are predominant in DLB, Iodine-123 FP-CIT SPECT
is of diagnostic value [31]. The characteristic sympathetic
denervation in DLB can be assessed using Iodine-123-
MIBG in a very speciﬁc manner [29]. Given the fact that
SPECT scanners are available in many larger hospitals, the
diﬀerential diagnosis of FTD and DLB against AD with
SPECT is feasible and clinicaly relevant, since antidementive
drugs like cholinesterase-inhibitors are unlikely to be of
therapeutic beneﬁt in FTD, but are approved for AD,
Parkinson’s disease dementia (PDD) and are beneﬁcial in
DLB (positive therapeutic studies, but oﬀ-label use).
7.Technical Improvements
The image acquisition technique in SPECT is prone to signal
degradation due to diﬀerent physical phenomena like depth-
dependent blurring, photon attenuation and scattering.
SPECT images are evaluated similar to other imaging
techniques like MRI or CT, inferring bias due to subjective
image interpretation. Technical limitations in the past made
iterativeimagereconstructionnecessary [33].Inrecentyears,
considerable advances have been made in this area like the
introduction of hybrid SPECT/CTdevices (for simultaneous
registration of anatomy and function) and optimized, fast
imaging reconstruction hard- and software. These advances
nowallowimprovedcalibrationandquantiﬁcationofSPECT
images. The coregistration of SPECT images with structural
imaging and advances in automated anatomical labeling
(AAL) opened the possibility to identify voxels of interest4 International Journal of Alzheimer’s Disease
(VOI) which increases the originally limited spatial resolu-
tion of SPECT ultimately leading to better discrimination
of AD patients. In addition, Pagani et al. [34]a sw e l la s
Merhof et al. [35] has recently shown that rCBF patterns
together with anatomical information can be subjected
to principal component analysis (PCA) resp. multivariate
analysis, which allows to draw further conclusion about
disturbed functional connectivity between brain regions in
dementia.Perfusion imagingusing arterialspin labelingMRI
is a standard technique in cerebrovascular disease and has
been applied to AD diagnosis and diﬀerential diagnosis to
FTD with promising results [36, 37] but the exact diagnostic
value parameters likesensitivity, speciﬁcity have not yet been
delineated in detail.
8.AreasofUncertainty
It is still unclear whether the “AD pattern” in perfusion
SPECT merely reﬂects cortical neurodegeneration or the
secondary cholinergic deﬁcit following degeneration of the
basal nucleus of Meynert. Studies that both investigated
CSF biomarkers and SPECT showed no correlation [5, 38].
Simultaneous registration of the cholinergic deﬁcit (e.g.,
using Nicotinic 123I-5IA-85380 SPECT [39]) and perfusion
SPECTorAmyloid-PET with perfusion SPECTcouldhelp to
resolve this issue.
In perfusion SPECT usually lobar hypoperfusion is regis-
trated. More recently, MRI techniques have shown that there
is also compensatory hyperperfusion in AD and FTD [36].
Possible underlying mechanisms are partial deaﬀerentation
or a cognitive reserve mechanism. It would be interesting to
conﬁrmtheseresultsinperfusion SPECT,resp. toexplorethe
diagnostic value of hyperperfusion in correlation to reserve
variables.
9.Conclusions
Perfusion SPECT and FDG-PET are metabolic based and
were the ﬁrst methods of “functional” brain imaging in
Alzheimer’s disease showing hypoperfusion in the temporo-
parietal regions with the highest load with plaques and
tangles in postmortem brains with AD.
This has lead to a widespread use of perfusion SPECT
and FDG-PET as a diagnostic tool in AD. Since speciﬁcity
exceeds sensitivity the diagnostic value of perfusion SPECT
to rule out AD usually is higher than to conﬁrm it. However,
accuracy of any diagnostic tool is critically dependent on
disease severity and the population under investigation.
In addition, perfusion SPECT is useful in discriminat-
ing vascular dementia, FTD, and DLB in the absence of
validated speciﬁc biomarkers for these conditions. More
recently pathophysiology-based CSF-biomarkers, especially
beta-amyloid peptide-42 and tau protein, have been inves-
tigated with a diagnostic accuracy that seems to be superior
to perfusion SPECT and FDG-PET. In addition, due to their
direct reﬂection of the underlying process, CSF biomarkers
(alone or in combination) are also suited for early diagnosis,
for example, in patients with MCI, where the diagnostic
value for SPECT is even lower than in prevalent AD. In
contrast to CSF assays, PET biomarkers have the advantage
of showing the anatomic distribution of pathology and were
ﬁrst available for amyloid plaques (11CP i B ) .N o w ,t h e r ei s
development of longer-lasting 18F PET tracers as well ﬁrst
evidencethatplaquesandtanglescanbeimagedwithasingle
PET compound, but the results have to be conﬁrmed in
independent studies.
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